SNDX241220C20000
- 0.10
- 0.000.00%
Syndax Pharmaceuticals Newsroom
Trending Stocks Today | U-BX Technology Surges 55.86% Post-Market
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $42 to $51
A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $25 to $51
Syndax Pharmaceuticals (SNDX) Receives a Buy From Stifel Nicolaus
Syndax Pharmaceuticals (SNDX) Gets a Buy From TD Cowen
While Syndax Pharmaceuticals (NASDAQ:SNDX) Shareholders Have Made 85% in 5 Years, Increasing Losses Might Now Be Front of Mind as Stock Sheds 6.8% This Week
Syndax Pharmaceuticals Price Target Maintained With a $51.00/Share by HC Wainwright & Co.
Syndax Pharmaceuticals Analyst Ratings
Edward White Issues Buy Rating for Syndax Pharmaceuticals Due to Promising Revuforj Data and Market Potential
Barclays Releases a Buy Rating on Syndax Pharmaceuticals (SNDX)
Analysts Conflicted on These Healthcare Names: Revance Therapeutics (RVNC), Syndax Pharmaceuticals (SNDX) and Align Tech (ALGN)
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), UnitedHealth (UNH) and Disc Medicine (IRON)
Syndax Announces Additional Data From AUGMENT-101 Trial Of Revuforj
Express News | Syndax Pharmaceuticals Inc -Plans to Initiate Pivotal Trial With This Combination in Front-Line Newly Diagnosed Patients by Year-End 2024
Express News | Syndax Pharmaceuticals: Subgroup Analyses From Ph 2 Protocol-Defined R/R Mnpm1 Aml Efficacy Population Show Responses Across All Major Subgroups
Syndax Announces Additional Positive Data for Revuforj (Revumenib) From AUGMENT-101 Trial in Relapsed or Refractory MNPM1 AML and BEAT AML Frontline Combination Trial
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $25
Positive Outlook for Syndax Pharmaceuticals Amid Efficacy and Safety Considerations
Reported Saturday, Syndax's Revuforj (Revumenib) Achieves High Response Rates In Acute Leukemia Trials, Presents Compelling Data At ASH 2024
Express News | Syndax Presents Positive Revuforj® (Revumenib) Data in Acute Leukemias From Multiple Trials, Including the Save Combination and Augment-101 Trials, at 66TH Ash Annual Meeting